Introduction of the Annual Report 1. Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5.

Slides:



Advertisements
Similar presentations
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Advertisements

National experiences of regular price monitoring Klara Tisocki, WHO/HAI medicine price project Towards equitable and affordable medicine prices policy.
Results of the Jordan medicine price and availability survey conducted in 2004.
Medicine Prices Matter to People and Insurance Companies Margaret Ewen Health Action International.
Impact of JUSFTA on affordability and availability of medicines from perspective of local generic manufacturers Towards equitable and affordable medicine.
Strategies to improve the acceptance and use of generics. Jordan Pharmaceutical Association Dr.Taher Shakhashir.
Direct costs and availability of diabetes medicines in low-income and middle-income countries Birgit Volman 27/08/2008 Meeting on Access to Medicines for.
JFDA & HAI Workshop Towards equitable and affordable medicine prices policy in Jordan 4-5 December 2007 Strategies to aid market entry and competition.
1 Paying the Price Margaret Ewen Health Action International Europe.
1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
August 27th Availability, Pricing and Affordability of Asthma Medicines Presentation for Meeting on Availability, Pricing and Affordability.
1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.
Strategies to Improve Efficiency in Medicine Procurement Towards equitable and affordable medicine prices policies in Jordan Workshop 4-5 Dec, 2007 Dr.
MEDICINES PRICES IN INDONESIA Ms. Selma Siahaan Center for Health Services and Technology R&D National Institute of Health R&D Indonesia 14 June 2006.
1 Medicine Availability, Prices and Affordability in West Bengal, India (2004) DALIA DEY CUTS & CDMU.
1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.
Lebanon, 2004 Medicine price survey in Lebanon, 2004 undertaken by Dr Rita Karam, Ministry of Health Marg Ewen (on behalf of Dr Karam) WHO/HAI post-medicine.
Overview of the medicine prices and availability survey methodology Presentation template for adaptation and use in medicine prices and availability survey.
Syria,2004 Medicine price survey in Syria, 2004 undertaken by Pharmaceutical Studies Directorate, Ministry of Health Presentation by Razan Sallouta WHO/HAI.
A MEDICINE PRICES SURVEY IN CHINA Presentation by Dr Xiaoxia Hu Research by Dr Sun Qiang and Dr Xiaoxia Hu June, 2006.
1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.
Mohamed Izham Mohamed Ibrahim
August 27th Availability, Pricing and Affordability of Cardiovascular Medicines Draft report for comments Maaike S.M. van Mourik University.
The prices of medicines worldwide & how they are determined Margaret Ewen Health Action International Europe Co-ordinator WHO/HAI Project on Medicine Prices.
Measuring Medicine Prices and Availability – a new Methodology and few Indian Survey Results Dr. Anita Kotwani Department of Pharmacology Vallabhbhai Patel.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Price, availability and affordability of medicines international comparison of 29 surveys Presented by: Richard Laing World Health Organization, Geneva.
Essential Medicines & Pharmaceutical Policies DHS/EMRO WHO Perspective on Medicine Prices & Policies Meeting of Drug Board on Medicine Pricing Federal.
Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.
MEASURING LABOUR FORCE PARTICIPATION OF WOMEN
THE 2004 LIVING CONDITIONS MONITORING SURVEY : ZAMBIA EXTENT TO WHICH GENDER WAS INCORPORATED presented at the Global Forum on Gender Statistics, Accra.
David Burdett May 11, 2004 Package Binding for WS CDL.
THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.
THE COMMONWEALTH FUND Why Not the Best? Results from the National Scorecard on U.S. Health System Performance, 2011 Cathy Schoen, Senior Vice President.
1. 2 Why are Result & Impact Indicators Needed? To better understand the positive/negative results of EC aid. The main questions are: 1.What change is.
1 MDG Target 8.E gap analysis Dr Hans Hogerzeil Director, Department of Essential Medicines and Pharmaceutical Policies, World Health Organization October.
1 RA I Sub-Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Casablanca, Morocco, 20 – 22 December 2005 Status of observing programmes in RA I.
Joint ITU/ECA Regional Workshop on Information and Communication Technologies (ICT) Indicators Gaborone, Botswana October 2004
Undergraduates in Minnesota: Who are they and how do they finance their education? Tricia Grimes Shefali Mehta Minnesota Office of Higher Education November.
Break Time Remaining 10:00.
Amanullah Saif Cost Accountant, Drug Control Administration Government of Pakistan Relationship between Tariffs, Prices and Consumption of Interferon.
1 RA III - Regional Training Seminar on CLIMAT&CLIMAT TEMP Reporting Buenos Aires, Argentina, 25 – 27 October 2006 Status of observing programmes in RA.
Medicine prices: a WHO/Health Action International collaboration The approach, some results, and implications for policy to improve the affordability of.
7/16/08 1 New Mexico’s Indicator-based Information System for Public Health Data (NM-IBIS) Community Health Assessment Training July 16, 2008.
Copyright © 2008 Pearson Addison-Wesley. All rights reserved. Chapter 10 A Monetary Intertemporal Model: Money, Prices, and Monetary Policy.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 3 rd 2010 Alexandra Cameron, Department of Essential Medicines.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
1 Generating reliable evidence: measuring medicine prices and availability Dr Richard Laing Department of Essential Medicines and Pharmaceutical Policy.
Essential Medicines Programmes Sudan now Essential Medicines Programmes Sudan now.
Analysis of the Pharmaceutical Supply Chain in Jordan Simon Conesa 1, Prashant Yadav 1, Rania Bader 2 (2009) 1 MIT-Zaragoza International Logistics Program,
Paying the Price: The Affordability of Medicines Across the Commonwealth (and elsewhere) Margaret Ewen Health Action International.
Wilbert Bannenberg SARPAM
1 Availability, price and affordability of cardiovascular medicines Richard Laing for Alexandra Cameron & Maaike van Mourik International Conference.
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, November 18 th 2009 Alexandra Cameron, Department of Essential Medicines.
ASSESSMENT OF AVAILABILITY, PRICE AND AFFORDABILITY OF MEDICINES FOR CHILDREN IN GHANA Authors: Gyansa-Lutterodt M. 1,Andrews Annan E. 2, Koduah A. 1,
Medicines prices: measurement and findings in countries Richard Laing PSM - WHO Gilles Forte TCM - WHO Margaret Ewen HAI - Europe.
Medicine Prices, Availability, Affordability and Price Components in Kazakhstan, Kyrgystan, Tajikistan & Uzbekistan Margaret Ewen Health Action International.
Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
BASELINE SURVEYS AND MONITORING OF PHARMACEUTICAL SITUATION IN COUNTRIES. Joseph Serutoke NPO/EDM WHO Uganda November 2002.
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Paying the price: Medicine prices, availability and affordability across the globe Alexandra Cameron Department of Essential Medicines and Pharmaceutical.
1 Medicine price and availability surveys – methodology essentials – policy options Richard Laing Department of Essential Medicines and Pharmaceutical.
Out-of-pocket and Out-of-reach Margaret Ewen, Coordinator, Global Projects (Pricing) Health Action International Amsterdam.
MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda.
1 Medicine prices and availability, evidence for policy Technical Briefing Seminar, 2012 Richard Laing with materials provided by Alexandra Cameron, Department.
Health Care Financing Health Economic Course Series
Medicine prices and availability, evidence for policy
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies Introduction and Overview May 30 to June 4, 2005 Abuja, Nigeria.
Presentation transcript:

Introduction of the Annual Report 1

Workshop towards equitable and affordable medicine prices policy in Jordan Dead Sea, Jordan Dead Sea, Jordan 4–5 December 2007 Mohamed Bin Shahna TO/EMPWHO/EMRO Results of medicines price surveys across the Eastern Mediterranean Region

Outline 1. Introduction 2. Determinants of access to medicines 3. Medicine price surveys in the Region 4. Important findings from the surveys 5. Recommendations

Introduction Medicines are a vital component of the health care system Ensured access to essential medicines is part of the fulfilment of the right to health Medicines are the second largest expenditure in the public health budget in developing countries, and a very high proportion of household spending Medicine prices are directly affected by intellectual property rights issues

Expenditure on medicines from 9 national health accounts (NHA studies in the Region) 40% of total health expenditure is on medicines Up to 30% of the recurrent budget of ministries of health is spent on medicines Out-of-pocket expenditure is high Egypt: 53% of all medicines are purchased directly by households Morocco: 74%

Work on medicine price issues in EMR since October pre-survey training workshops and 2 post-survey workshops (regional/subregional) 11 national surveys conducted in the region 9 summary reports on survey findings in press Regional synthesis paper on survey findings in press Regional paper on pricing policies in press Country profiles for medicine pricing policies are being developed Hosted WHO/HAI global project meeting in Nov/Dec 06 RC54 technical paper on medicine price, availability, affordability and price component issues in EMR; resolution passed Jordan policy workshop Dec 07 (currently)

Outline 1. Introduction 2. Determinants of access to medicines 3. Medicine price surveys in the Region 4. Important findings from the surveys 5. Recommendations

Determinants of access to medicines A third of the population in the world and more than 50% of the population in developing countries do not have reliable access to medicines WHO has formulated a four-part framework for improving access to medicines

1. Rational selection and use 4. Reliable health and supply systems 2. Affordable prices 3. Sustainable financing ACCESS WHO Framework for Improving Access to Medicines

Outline 1. Introduction 2. Determinants of access to medicines 3. Medicine price surveys in the Region 4. Important findings from the surveys 5. Recommendations

Medicine price surveys #CountrySurvey yearConducted Medicines surveyed Core listLocal ListTotal 1Egypt2004Ministry of HealthDesk survey 2Jordan2004Jordan FDA Kuwait2004Academic Lebanon2004Ministry of Health Morocco2004Ministry of Health Pakistan2004NGO290 7Sudan2005Ministry of Health Syrian Arab Republic 2003Ministry of Health Tunisia2004Ministry of Health United Arab Emirates 2004Ministry of HealthDesk survey Field survey in 2006/7 11Yemen2006Ministry of Health27835

Outline 1. Introduction 2. Determinants of access to medicines 3. Medicine price surveys in the Region 4. Important findings from the surveys 5. Recommendations

Yemen 16/35 medicines were not found in any facility 29/35 medicines were available only in 4 facilities Pakistan 23/29 medicines were not found in more than 15 facilities Lebanon Only 15 of the 32 surveyed medicines were found in 20 public facilities Morocco 20/34 medicines were not available in more than half the health facilities

Public sector availability

Generally, ministries of health were found to obtain good procurement prices compared to International Reference Prices (IRPs) except Morocco: 3.7 times the IRPs Same generic medicine – wide differences between countries Ciprofloxacin: in Jordan the price was 0.6 times the IRP whereas in Morocco the same medicine was procured at 25.5 times the IRP All countries except Egypt, Pakistan and Sudan were found to be buying at least some medicines in both generic and branded forms

MPRs adjusted for inflation, exchange rates and standardised to MSH 2003 prices (base year 2004)

Private sector retail prices were found to be excessive generally for both generic and branded medicines Sudan: 18 times the IRPs for branded medicines Most countries were found to have prices for generic medicines that were 5 times the IRPs Only Pakistan and the Syrian Arab Republic had prices for generics that were less than 5 times the IRPs Kuwait had only a small difference between branded and generic medicines, about 10%

Private sector retail prices MPRs adjusted for exchange rates, inflation and purchasing power parity (PPP) and standardised to MSH 2003 prices (base year 2004)

Difference between the brand price and the price of the lowest priced generic In the private sector: Sudan: 3.7 brand premium, i.e. branded medicines were 3.7 times the price of the equivalent generic medicine Kuwait: only 1.1 brand premium, e.g. median price ratios for originator brand and lowest priced generic products respectively were 50.2 and 47.4 for atenolol, and and for ciprofloxacin

Respiratory infection: 2.4 days income to buy a weeks supply of branded amoxicillin in Jordan Depressive illness: 7.7 days income to buy a months supply of generic fluoxetine in Pakistan and 36.4 days income to buy branded fluoxetine Ulcer: One months treatment with generic omeprazole – 2.9 days income in Sudan and 19.3 days income in Jordan; with originator brand 10.6 days income in Morocco and 23.7 days income in Pakistan Number of days income a lowest paid government worker has to spend to buy pre-selected treatment regimes for 9 common diseases

CountryPort/ clearance etc. Other fees TaxImporter/ wholesaler mark-up Retailer mark-up Total cumulative mark-up Jordan (imp) 3.5% 0.2%4%19%26%61.8% Kuwait (imp) ––– 35%26%70.1% Lebanon (imp) 11.5% –– 10%30%59.5% Lebanon (local) ––– 10%30% – Morocco (imp) Fees – 7%10%30%53.4% Sudan (imp) 11.5%8% – 15%20%66.7% Syria (local) – 8% – 8-30%19.9% Yemen (imp) 6%7%5%10%20%57.4%

The impact of survey findings Examples Lebanon: 2004: FOB prices of 25% of all registered medicines (1100 medicines) reduced by 20%–30% & budget increased for cancer, HIV & other specialised medicines from $14M per annum to $40M 2006: Information on patient prices & pharmacy margin included on MoH website 2007: National formulary published & reviewed price structure of locally manufactured medicines 2008/2009: implementing a re-pricing scheme for all medicines to reduce FOB price UAE: lower medicine prices by 7-8% Morocco: discussed options to reduce prices

Outline 1. Introduction 2. Determinants of access to medicines 3. Medicine price surveys in the Region 4. Important findings from the surveys 5. Recommendations

Recommendations 1.Ensure good governance in the health and pharmaceutical sector 2.Develop an effective pharmaceutical sector as part of a strengthened health system 3.Strengthen the national regulatory authority National medicines policy; essential medicines list; transparency and accountability; monitoring Financing; human resources development; medicine supply systems; information Institutional development; independence; transparency

Recommendations 4.Improve availability and the obtaining of better prices in public sector procurement of medicines 5.Reduce medicine prices in the private sector 6.Rationalize taxes and mark-ups on medicine Realistic quantification; purchasing generics; pooled procurement; using appropriate IRPs; comparing procurement prices Review of medicine pricing policy; effective regulation In-depth analysis of price structure; tax exemption for essential medicines; rationalization of mark-ups

What will be done at the regional level 1.Online availability of public procurement prices 2.Online availability of international reference prices 3.Support medicine price surveys and regular monitoring of medicine prices Tender prices; EMRO Medicine Prices Hub For better comparisons with international best prices 4 new surveys; ongoing monitoring

What will be done at the regional level 4.Development of medicine pricing policy packages for Member States Technical assistance in development of generic policies based on best practices

still a long way to go!

شكراً Thank You Merci Danke